An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This open-label, multi-center study in a local environment will evaluate the safety and the
effect on disease activity with regard to reduction in signs and symptoms over 6 months of
treatment in patients with moderate to severe active rheumatoid arthritis who experienced an
inadequate response to a non-biologic DMARD. Tocilizumab 8 mg/kg will be administered as an
intravenous infusion every 4 weeks for a total of 6 infusions as monotherapy or in
combination with methotrexate (MTX). The anticipated time of study treatment is 24 weeks.